

GSC Advanced Research and Reviews

eISSN: 2582-4597 CODEN (USA): GARRC2 Cross Ref DOI: 10.30574/gscarr Journal homepage: https://gsconlinepress.com/journals/gscarr/

(RESEARCH ARTICLE)

Check for updates

Trends and morphologic variants of Kaposi Sarcoma as seen in Nnewi, Anambra State, Nigeria

Felix Emeka Menkiti ^{1,*}, Cornelius Ozobia Ukah ¹, Ifeoma Oluchukwu Menkiti ², Chisom Godswill Chigbo ³ and Igwebuike Victor Onyiaorah ¹

¹ Department of Anatomic Pathology and Forensic Medicine, Nnamdi Azikiwe University, Nnewi Campus, Anambra state, Nigeria.

² School of Nursing, Nnamdi Azikiwe University Teaching Hospitals, Nnewi, Anambra State, Nigeria.

³ Research society, Nnamdi Azikiwe University Teaching Hospitals, Nnewi, Anambra State, Nigeria.

GSC Advanced Research and Reviews, 2022, 13(01), 125–132

Publication history: Received on 05 September 2022; revised on 10 October 2022; accepted on 13 October 2022

Article DOI: https://doi.org/10.30574/gscarr.2022.13.1.0269

Abstract

Kaposi sarcoma (KS) is a human herpes virus type 8 (HHV-8) driven neoplasm with varying morphologic features and attendant diagnostic dilemma. This study presents the trend of KS in our environment and the different morphologic variants, with a view to arousing awareness and reducing missed and delayed diagnosis. KS accounted for 18.34% and 59.66% of vascular neoplasms and malignant vascular neoplasms, respectively with most KS occurring in the background of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). The frequency peaked in 2013 and began to decline with a fairly even sex distribution. There are diverse variants of KS that can pose diagnostic challenges. Hence, there is need for this awareness to enhance prompt and accurate diagnosis.

Keywords: Kaposi Sarcoma; Morphology; Trends; Variants; Vascular

1. Introduction

Over the past few decades, the interest in Kaposi sarcoma (KS) has been renewed due to its association with HIV/AIDS. KS is one of the AIDS defining neoplasms, classified as a low grade sarcoma. KS presents in four epidemiological forms, including classic, endemic, iatrogenic, and AIDS-associated, all having a common aetiologic agent HHV-8 (Human Herpes Virus-8).¹The incidence of KS has decreased globally since the advent of highly active anti-retroviral therapy (HAART) for the treatment of HIV/AIDS.² According to GLOBOCAN 2020, KS ranked 33rd among cancer cases, accounting for 0.18% of new cancer cases worldwide,³ but ranks 20th in Nigeria, accounting for 0.94% of new cancer cases with a cumulative risk of 0.06.⁴ In a study done in South-eastern part of Nigeria, KS accounted for 1.31% of solid cancers and 15.38% of sarcomas.⁵

Accurate diagnosis requires morphologic evaluation, with KS being characterised by vascular slits formed by atypical spindle cells containing red cells and admixed with inflammatory cells and occasional hyaline globules.⁶ However, morphology alone is not sufficient to confirm diagnosis or exclude mimics of KS. Hence, the need to subject lesions with features suggestive of KS to immunohistochemical confirmation.^{5,7} Moreso, in recent times, there has been an increasing awareness and reporting of wider histologic variants of KS, some of which are unusual and easily missed.⁸⁻¹⁰ Some researchers have opined that some of these variants may have prognostic implication; hence failure to identify a given lesion as KS could lead to delayed diagnosis or inappropriate management.¹¹ Pathologists therefore, must be aware of this to avoid misdiagnosis, which is common with KS and KS-like lesions.⁵

Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

^{*} Corresponding author: Felix Emeka Menkiti

Department of Anatomic Pathology and Forensic Medicine, Nnamdi Azikiwe University, Nnewi Campus, Anambra state, Nigeria.

This study is aimed at assessing the trend of KS and the different morphologic patterns as seen in Nnewi, Anambra state Nigeria over a 16-year period. This is to highlight and create awareness of these pictures to reduce misdiagnosis, as well as encourage utilisation of confirmatory tests on KS-like lesions.

2. Material and methods

This is a descriptive 16 years retrospective study that involved all biopsies with a morphologic diagnosis of KS and confirmed using HHV-8 LNA1 immunohistochemistry. The formalin-fixed paraffin-embedded tissue blocks and clinical request forms of cases that met inclusion criteria were retrieved from the archives of Histopathology Department of Nnamdi Azikiwe University Teaching Hospital (NAUTH)and Pathocon Specialist Clinic & Research Institute, both in Nnewi, Anambra State, Nigeria, between the period of January 2006 and December 2020. Fresh sections were prepared and stained with haematoxylin and eosin (H and E) stains and examined using multi-headed compound light microscope (@CARL ZEISS).

The data analysis was done using the IBM, Chicago Statistical Package for Social Sciences (SPSS) software version 20.0, and the results presented in tables and charts.

3. Results

A total of 387 vascular lesions were recorded in the years under review (including 223 benign, 45 borderline and 119 malignant vascular lesions), 71 of which were diagnosed morphologically and immunohistochemically (using HHV-8 LNA1 antibody) confirmed as KS. KS therefore accounted for 18.34% and 59.66% of vascular neoplasms and malignant vascular neoplasms, respectively.

KS was noted to be at its peak in the third decade, affected 35 males and 36 females in a male to female ratio of 1.0:1.0; however, more females (58.93%) were affected by the HIV/AIDS-associated KS (see *Table 1*).

Age range	HIV/AIDS-Associated		Non-HIV/AIDS-Associated		Total
	Male	Female	Male	Female	Total
1-10	1	1	1	0	3
11-20	1	1	2	0	4
21-30	8	11	1	0	20
31-40	4	9	1	0	14
41-50	5	6	2	1	14
51-60	3	3	1	1	8
61-70	1	2	1	1	5
71-80	0	0	3	0	3
	23	33	12	3	71
Total	56		15		

Table 1 Demographic distribution of KS

Almost 80% (56/71) of the KS lesions were associated with HIV/AIDS. Most (41/71) of the lesions were noted to involve the lower limbs (*Figure 1*). These lesions were largely diagnosed at the morphologic nodular stage (see *Figure 2*).




Figure 1 Anatomic site distribution of KS




Figure 2 Morphologic stage distribution of KS

Figure 3 showed a gradual decline in the frequency of KS from 2006 to 2011, a sharp rise thereafter to reach a peak in 2013, followed by a gradual decline. The rise was noted to be largely in association with HIV/AIDS (see *Figure 4*) with a fairly uniform distribution in both sexes (see *Figure 5*).




Figure 3 Yearly trend of Kaposi Sarcoma across the year 2006-2021




Figure 4 Yearly trend of KS according to classification across year 2006-2021




Figure 5 Gender trend of Kaposi Sarcoma across the year 2006-2021

3.1. Morphologic variants of KS observed

Figures 6 (a-h) show the morphologic variants noted in this review, other than the classic morphologic pictures of the different stages. These included epithelioid, cavernous haemangioma-like, lymphangioma-like, telangiectatic, bullous-type, pyogenic granuloma-like, micronodular, acanthotic and verrucous variants.

Epithelioid KS consisted of sheets and nests of epithelioid cells having pleomorphic and irregular nuclei with scant cytoplasm. There are extravasated red blood cells, numerous mitotic figures and scattered inflammatory cells (see *Fig 6a*). Telangiectatic KS is composed of variably sized, ectatic, congested vascular channels amidst foci of typical nodular KS (see *Figures 6b-d*) lined by HHV8-LNA-1 positive endothelial cells. *Cavernous haemangioma-like KS* shows cavernous channels with flattened endothelium admixed with plump spindle cell proliferation interspersed by vascular slits, inflammatory cells and extravasated red cells under a hyperkeratotic squamous epithelium; the spindle and endothelial cells being HHV-8 LNA1 positive (see *Figures 6e-f*). *Pyogenic granuloma-like* is characterized by lobulated capillary-caliber vascular proliferation with features consistent with KS spindle cell proliferation and HHV8-LNA-1 immunopositivity (see *Figures 6g-h*). *Lymphangioma-like KS* shows dermal inter-anastomotic, irregularly shaped, caving and variably atypical endothelial-lined channels in a background of typical KS spindle cells (see *Figures 6i-j*). *Acanthotic KS* displays dermal atypical spindle cells interspersed by inflammatory cells and slit-like channels containing red cells with overlying acanthotic and hyperkeratotic epidermis (see *Figure 6k*). *Micronodular KS* shows a small, circumscribed but unencapsulated, proliferating atypical spindle cell characteristic of KS within the reticular dermis (see *Figure 6l*). *Bullous KS* features consistent with KS lesions, but the overlying epidermis has sub-epidermal bullae,

and the cells were positive for HHV-8 LNA1 immunostaining (see *Figures 6m-n*). *Verrucous KS* shows verruciform epidermal hyperplasia and hyperkeratosis overlying a dermal characteristic KS lesion (see *Figure 6o*).

Figure 6 Photomicrographs showing the different morphologic variants epithelioid (a: H&E x100), telangiectatic (b: H&E x100), cavernous haemangioma-like (c: H&E x100), pyogenic granuloma-like (d: H&E x50), lymphangioma-like (e: H&E x100), acanthotic (f: H&E x50), micronodular (g: H&E x50), Bullous (h: HHV8 immunohistochemistry x100) and verrucous (i: HHV8 immunohistochemistry x50).

4. Discussions

KS is a Human Herpes Virus-8 (HHV-8) driven neoplasm with variable clinical course and occurring in four epidemiological setting.¹² It was first reported by Moritz Kaposi in 1872. Its incidence was reportedly increased over the years linked to HIV/AIDS pandemic but has declined globally due to the introduction of HAARTS, accounting for about 0.2% of cancer incidence and mortality.¹³ despite this global decline, KS still accounts for 0.94% and 0.87% of cancer incidence and mortality respectively, with a 5-year prevalence of 1.20%.¹⁴

KS accounted for 18.34% and 59.66% of vascular neoplasms and malignant vascular neoplasms, respectively, making it the commonest malignant vascular lesion in this study. A study done in northern Nigeria reported KS as the most common malignant vascular neoplasm.¹⁵ Forae *et al.* in the south south part of Nigeria also reported that KS accounted for 79/269 vascular lesions diagnosed over 20 years period, accounting for approximately 89% of borderline and malignant vascular neoplasm.¹⁶ KS is therefore a fairly common vascular neoplasm in our environment. KS has been reported to occur over a wide age range with a peak that varies between the third and fifth decades of life.¹⁷⁻¹⁹

The trend over the years indicated a steady growth from 2006 to 2013, after which there was a sharp decline, a stepwise rise and then a stepwise steady decline. We noted here that the burden of KS over the years was majorly contributed to by the HIV/AIDS association, which has slight female preponderance; though KS overall displays a fairly even sex distribution. The study by Forae *et al.* indicated a rise after year 2005 to reach a peak in 2008, then a little drop to a still significant value that is fairly sustained between 2009 and 2014.¹⁶ We may not fully define the reason for the initially rise in our study, but could be possibly explained by increased campaign and awareness of HIV/AIDS and testing as coordinated by the establishment of national agency for the control of AIDS (NACA) and a National Strategic Framework in 2004/2005.²⁰ It is plausible to state that a sustained strategic plan against HIV/AIDS with targeted reach of the rural communities, is still required, not only to eradicate the HIV/AIDS pandemic but also KS.

KS is morphologically characterized by spindle cells forming slits containing red bloodcells, admixed with inflammatory cells and occasional presence of periodic acid-Schiff (PAS)stain positive hyaline globules.¹⁰However, KS clearly has the ability to develop into lesions of varying morphologic appearance relating to the stages of the lesion, including patch, plaque and nodular stages. Most of the lesions in this study were morphologically diagnosed at the nodular stage and, the lower limb is the commonest affected anatomic site. This finding is similar to that reported in studies related to KS in most studies in Africa. Although this late morphology (nodular stage) may be related to late presentation due to ignorance, poverty and poor access to health care in Africa, as well as the fact that most are HIV/AIDS-associated, thus having rapid progression,²¹ no explanation has been given for the lower limb predilection of this lesion.

We noted in this study some morphologic variants other than the conventional type. These included epithelioid, cavernous haemangioma-like, lymphangioma-like, telangiectatic, bullous-type, pyogenic granuloma-like, micronodular, acanthotic, verrucous and hyperkeratotic variants. The morphologic diversities of KS have been reported in literatures, noting various variants.²²⁻²⁴ It has also been suggested that certain variants, such as anaplastic KS and possibly lymphangioma-like KS, might have prognostic relevance.²⁵⁻²⁶ It is therefore important that pathologists be able to recognize these variants in order to avoid potential misdiagnosis, delayed diagnosis and mismanagement of afflicted patients.

5. Conclusion

KS presents varying morphologic diversities that pathologists and clinicians must be aware of to enhance prompt and accurate patient management. No gender predilection is noted in the occurrence of KS. There was a noticeable steady decline in its frequency in this last decade. Since its occurrence over time is related to HIV/AIDS, a sustained, coordinated, grassroots action against HIV/AIDS will help reduce the frequency in our environment.

Compliance with ethical standards

Acknowledgments

The authors acknowledge the staff of Histopathology department, Nnamdi Azikiwe University Teaching Hospital and Pathocon Specialist Clinic & Research Institute, both in Nnewi, Anambra State, Nigeria for their assistance in data collection and preparing the slides used in this study.

Disclosure of conflict of interest

All the authors declare that there are no conflicts of interest.

References

- [1] Weiss SW, Goldblum JR. Soft tissue tumors of intermediate malignancy of uncertain type. In: Weiss SW, Goldblum JR, editors. Enzinger and Weiss's Soft Tissue Tumors. 5th ed. Mosby, London, UK: Elsevier; 2008. p. 1101–1108.
- [2] American cancer society [Internet]. Key statistics about Kaposi sarcoma. Atlanta, Georgia: ACS; 2018 [Updated 2018 April 19; cited 2022 March 17]. Available from: https://cancer.org/1.800.227.2345.
- [3] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics, 2020: GLOBOCAN estimates of Incidence and Mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-249.
- [4] International Agency for Research on cancer, World Health Organization. The global cancer observatory: Nigeria fact sheets [Internet]. GLOBOCAN 2020 [Updated 2021 March; cited 2022 March 17]. Available from https://gco.iarc.fr.
- [5] Menkiti FE, Ukah CO, Adelusola KA, Ezejiofor IF. Human herpesvirus-8 latent nuclear antigen-1 expression in Kaposi's sarcoma cases as seen in Nnewi, Anambra State: (A 10-year retrospective study). J Sci Soc 2020;47: 153-7.
- [6] Rosai J. Tumors and tumor-like conditions: Kaposi sarcoma. In: Rosai and Ackerman's Surgical Pathology. 10th Ed. China: Mosby Elsevier Inc; 2011. pp. 187-189.
- [7] Speicher DJ, Wanzala D, D'Lima M, Njiru A, Chindia M, Dimba E, et al. Diagnostic challenges of oral and cutaneous Kaposi's sarcoma in resource-constrained settings. J Oral Pathol Med. 2015; 44(10):842-849.
- [8] Ramdial PK, Miles E, Pillay B. The Emerging Histopathologic Diagnostic Challenges of Kaposi Sarcoma in the Acquired Immunodeficiency Syndrome Era. Austin J HIV/AIDS Res. 2016; 3(1): 1020.
- [9] Schwartz RA. Kaposi's sarcoma: an update. J SurgOncol.2004;87: 146-151.
- [10] Kyoung Bun Lee Hye Seung Lee Hee Eun Lee, et al. Immunohistochemical Characteristics of Kaposi Sarcoma Compared with Its Mimics. The Korean Journal of Pathology.2006; 40: 361-7.
- [11] Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol. 2008; 3: 31. doi: 10.1186/1746-1596-3-31.
- [12] Basra P, Paramo J, Alexis J. Disseminated Kaposi Sarcoma with Epithelioid Morphology in an HIV/AIDS Patient; A Previously Unreported Variant. J Cutan Pathol. 2018; 45(7):526-529. doi: 10.1111/cup.13254.
- [13] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin. 2021; 0: 1-41. https://doi.org/10.3322/caac.21660.
- [14] The International Agency for Research on cancer: WHO. The global cancer observatory: Nigeria fact sheets. GLOBOCAN 2020. March 2021. Accessed April 05, 2022 from https://gco.iarc.fr.
- [15] Yusuf I, Solomon R, Atanda AT, Umar AB, Imam MI, Sule AA. Vascular tumors inNorthern Nigeria: 10 Year Retrospective Review. Sahel Med J. 2018; 21: 83-7. DOI: 10.4103/SMJ_63_16.
- [16] Forae GD, Obaseki DE. Trends and Histopathological Patterns of Kaposi Sarcoma at The University of Benin Teaching Hospital, Benin City, Nigeria. Oman Medical Journal 2018; 33(4): 337-341.
- [17] Chalya PL, Mbunda F, Rambau PF, Jaka H, Masalu N, Mirambo M, et al. Kaposi Sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania. BMC Res Notes. 2015; 8:440.
- [18] Samaila MOA, Ayeni EI, Ahmed SA. Cancer pattern in a hospital-based registry. Arch Int Surg. 2015; 5:57-62. Doi:10.4103/2278-9596.158815.
- [19] Menkiti FE, Ukah CO, Menkiti IO, Ezejiofor IF, Adelusola KA. Immunohistochemical characterization of KS cases seen in Nnewi Anambra state using HHV-8 LNA1 and HIV-1p24 antibodies. World J Adv Rev Res. 2021; 11(03): 120-126. https://doi.org/10.30574/wjarr.2021.113.0436.
- [20] National Agency for the Control of AIDS: NACA. History of NACA. Available at www.naca.gov.ng 08/04/2022

- [21] Bogaert L. clinicopathologic proficiency in the diagnosis of Kaposi's sarcoma. ISRN AIDS. 2012. Doi:10.5402/2012/565463
- [22] Jessop S: HIV-associated Kaposi's sarcoma. Dermatol Clin. 2006:509-520; Schwartz RA, Micali G, Nasca MR, Scuderi L: Kaposi sarcoma: a continuing Conundrum. J Am Acad Dermatol 2008, 59:179–206.
- [23] Grayson W, Pantanowitz L: Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol. 2008, 25: 29–31.
- [24] Kandemir NO, Gun BD, Barut F, Yurdakan G, Bahadir B, Bektas S, et al.Histological Subgroups in classic Kaposi sarcoma: a preliminary study. Turkderm-Archives of the Turkish Dermatology and Venerology. 2010, 44: 73–78.
- [25] Cerimele D, Carlesimo F, Fadda G, Rotoli M, Cavalieri S. Anaplastic progression of classic Kaposi's sarcoma. Dermatology 1997, 194: 287-289.
- [26] Liebowitz MR, Dagliotti M, Smith E, Murray JF: Rapidly fatal Lymphangioma-like Kaposi's sarcoma. Histopathology. 1975; 4(5): 559-566